GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous ...
Continuous Glucose Monitoring Systems Market to reach USD 10.65B by 2034, driven by wearable devices, sensor innovation & ...
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...
Diabetes remains one of the nation’s most prevalent and dangerous chronic conditions, affecting nearly 15% of U.S. adults and causing more than 100,000 deaths each year. As a response, the landscape ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio The FDA has approved extending the use of ...
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of the first and only long-term, ...
Shares of DexCom (NASDAQ:DXCM) fell for the third straight session on Friday to reach the lowest level since April, even as ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of ...
This morning Belgian startup Indigo Diabetes announced a €38 million ($44.6 million) Series B funding round. This round included contributions from new investors Fund+, Ackermans&van Haaren, Capricorn ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...
Senseonics plans to take back full commercial control of its Eversense continuous glucose monitoring platforms from its distribution partner Ascensia Diabetes Care, as it aims to speed up | Senseonics ...
Zacks Investment Research on MSN
Is it the Right Time to Retain Abbott Stock in Your Portfolio?
Abbott ABT has consistently demonstrated strong growth and gained market share within its Nutrition business. Its Diabetes Care business continues to benefit from the growing sales of its flagship, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback